Here’s a quick look at the stocks likely to be in focus in today’s trade:
- FSN E-Commerce Ventures (Nykaa): The operator of Nykaa reported a 66% YoY increase in Q2FY25 net profit, reaching ₹13 crore, driven by a 24% revenue growth to ₹1,875 crore. EBITDA rose 29% YoY, with a margin improvement of 18 basis points to 5.5%. GMV also increased by 24% YoY.
- Hyundai Motor India: Hyundai saw a 16% decrease in net profit to ₹1,375.47 crore in Q2FY25, down from ₹1,628 crore in Q2FY24, citing weak demand and geopolitical challenges. This was its first earnings report since listing on the stock exchange in October.
- BSE Ltd: BSE posted a substantial 193% increase in net profit, reaching ₹346 crore, alongside a 138% rise in revenue to ₹746.3 crore for Q2FY25.
- Zydus Lifesciences: The company reported a 14% rise in net profit to ₹911 crore for Q2FY25, driven by strong domestic and US sales. Revenue increased 20% YoY to ₹5,237 crore.
- Sunteck Realty: Sunteck recorded a massive 348% YoY surge in net profit to ₹35 crore, with revenue from operations jumping 578% to ₹169 crore. Pre-sales for Q2FY25 rose 33% YoY to ₹524 crore.
- Tata Power: LIC divested over 2.02% of its stake in Tata Power, reducing its holding to 3.88%. The shares, worth approximately ₹2,888 crore, were sold over several months at an average price of ₹446.402 per share.
- PN Gadgil Jewellers: The jeweller reported a strong 46% revenue growth YoY, reaching ₹2,001.3 crore in Q2FY25, supported by festive demand and reduced gold import duties. PAT increased by 59% to ₹34.9 crore.
- Religare Enterprises: The financial services firm reported a 70% YoY rise in net profit to ₹68.49 crore for Q2FY25, with total revenue reaching ₹1,971 crore.
- Bosch: Bosch’s net profit declined 46% YoY to ₹536 crore for Q2FY25, despite a revenue rise to ₹4,394 crore.
- Natco Pharma: The pharma company reported an 83% YoY increase in net profit to ₹676 crore, with revenue growing to ₹1,371 crore for Q2FY25.
- Minda Corporation: Minda Corp posted a 25.42% increase in PAT, reaching ₹74 crore for Q2FY25, on a 7.9% rise in revenue to ₹1,290 crore, fueled by a broader customer base and premium products.
These companies’ Q2FY25 earnings reports indicate strong performance in various sectors, including pharmaceuticals, financial services, and auto parts manufacturing, while others face challenges due to market conditions. Investors will closely monitor these stocks for further developments.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
